相关实验视频

Updated: Sep 19, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

通过多 (ADP-ribose) 聚合酶-1 抑制剂治疗三阴性乳腺癌的治疗方法:当前更新

Agnidipta Das¹, Sudip Kumar Mandal², Swati Arya³

¹Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda 151401, Punjab, India.

Bioorganic chemistry

|June 1, 2025

概括

多 (ADP-Ribose) 聚合酶-1 (PARP-1) 抑制剂在治疗三阴性乳腺癌 (TNBC) 中表现有前途. 这些药物向DNA修复机制,为这种具有有限选择的侵袭性癌症亚型提供了新的希望.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

三阴性乳腺癌 (TNBC) 是一种缺乏ER,PR和HER2表达的侵袭性亚型.
青春期TNBC不成比例地影响年轻,更年期前和非洲裔美国女性,治疗途径有限.
BRCA1/2基因的突变与TNBC有关,突出显示了DNA修复途径作为治疗点.

研究的目的:

审查Poly (ADP-Ribose) 聚合酶-1 (PARP-1) 抑制剂在治疗TNBC中的重要性.
在TNBC的背景下探索PARP-1抑制剂的作用机制.
讨论TNBC管理中PARP-1抑制剂的当前和未来治疗前景.

主要方法:

文献综述侧重于PARP-1抑制剂及其在DNA修复中的作用.
在癌症治疗中研究PARP-1抑制剂 (Olaparib,Rucaparib,Niraparib,Talazoparib) 的研究分析.
检查关于TNBC中PARP-1抑制剂疗效的临床前和临床数据.

主要成果:

抑制PARP-1会破坏BRCA缺乏细胞中的DNA修复,导致合成致死性.
PARP-1 抑制剂显示出作为单疗法和TNBC联合治疗的潜力.
目前正在进行的研究探索优化PARP-1抑制剂的使用,以改善TNBC结果.

结论:

PARP-1 抑制剂代表了TNBC的一个有前途的治疗策略.
针对DNA修复途径提供了一种新的方法来对抗TNBC.
进一步的研究至关重要,以充分实现PARP-1抑制剂在TNBC治疗中的潜力.

关键词:

在HER2中,HER2是HER2.在状的中.这是一种PARP-1抑制剂.聚 (ADP-ribose) 聚合酶 (PARP) 是一种多 (ADP-ribose) 聚合酶.三阴性乳腺癌是三阴性乳腺癌.

更多相关视频

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.